期刊
AMERICAN JOURNAL OF GASTROENTEROLOGY
卷 107, 期 12, 页码 1770-1776出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1038/ajg.2012.117
关键词
-
资金
- Abbott Laboratories
- Abbott
- Ferring Pharmaceuticals
- Schering-Plough
- Shire Pharmaceuticals
- Therakos
- Norgine
- Tillotts Pharma
- Vifor
- Actelion
- MSD
- GSK
- Pfizer
- Ferring
- Falk
- Novo Nordisk
- Vifor Pharma
- UCB
- Merck
- Millennium
- Tillotts
- Engelheim
- Novartis
- Centocor
- Synta
- Elan/Biogen
- UCB Pharma
- Bristol-Myers Squibb
- Procter Gamble
- Genentech
- CombinatoRx
- ActoGeniX
- Janssen-Ortho
- Protein Design Labs
- ISIS
- Teva Pharmaceuticals
- Santarus
- Celgene
- Given Imaging
- Salix Pharm
- Ore Pharm
- GlaxoSmithKline
- Prometheus Therapeutics and Diagnostics
- Athersys
- Alba Therapeutics
- Axcan
- Shire
- Wyeth
- Zealand Pharm
- Cellerix
- MSD Laboratories
- Roche Laboratories
- UCB Laboratories
- AstraZeneca
- Cosmo Pharmaceuticals
- Takeda
- Nycomed
- Amgen
- Lilly
- Roche
- Abbott Japan
- Ajinomoto Pharma
- Asahi Kasei Kuraray Medical
- AstraZeneca Pharmaceuticals
- Janssen Pharmaceutical KK
- JIMRO Kyorin Pharmaceutical
- Otsuka Pharma
- Tanabe Mitsubishi Seiyaku
- UCB Japan
- UMN Pharma
- Zeria Pharmaceutical
- JBR Pharma
- Aesca
- Biogen IDEC
- ChemoCentryx
- Danonoe Austria
- Elan
- Lipid Therapeutics
- Ocera
- Otsuka
- PDL
- Pharacosmos
- Prometheus
- Yakult Austria
- 4SC
- Hoffmann-La Roche
- Albireo Pharma
- Bayer
- Boehringer Ingelheim
- Cosmo Technologies
- Danone Research
- Elan Pharmaceuticals
- Giuliani SpA
- Hutchison MediPharma
- Merck Sharp Dohme
- Neovacs
- Ocera Therapeutics
- Otsuka America Pharmaceutical
- Prometheus Laboratories
- Sanofi-Aventis
- Synta Pharmaceuticals
- Teva
- Asahi
- Cosmo
- Glenmark
- SigmoidPharma
- Vertex
- Warner Chilcott
- ActoGeniX NV
- AGI Therapeutics
- Albireo
- Alfa Wasserman
- AM-Pharma BV
- Anaphore
- Astellas Pharma
- Atlantic Healthcare
- Aptalis
- BioBalance
- Celegene
- Celek Pharmaceuticals
- Cellerix SL
- Cerimon Pharmaceuticals
- CoMentis
- Coronado Biosciences
- Cytokine Pharmasciences
- Eagle Pharmaceuticals
- Eisai Medical Research
- EnGene
- Eli Lilly
- Enteromedics
- Exagen Diagnostics
- Flexion Therapeutics
- Funxional Therapeutics
- Genzyme
- Gilead Sciences
- Human Genome Sciences
- Ironwood Pharmaceuticals
- Janssen
- KaloBios Pharmaceuticals
- Lexicon Pharmaceuticals
- Lycera
- Meda Pharmaceuticals
- Merck Research Laboratories
- MerckSerono
- Millennium Pharmaceuticals
- Nisshin Kyorin Pharmaceuticals
- NPS Pharmaceuticals
- Optimer Pharmaceuticals
- Orexigen Therapeutics
- PDL Biopharma
- ProtAb
- Purgenesis Technologies
- Receptos
- Relypsa
- Salient Pharmaceuticals
- Salix Pharmaceuticals
- Sigmoid Pharma
- Sirtris Pharmaceuticals (a GSK company)
- S.L.A. Pharma (UK)
- Targacept
- TxCell SA
- Viamet Pharmaceuticals
- Vascular Biogenics Limited (VBL)
- Warner Chilcott UK
- Procter & Gamble Pharmaceuticals
We report the findings and outputs of an international expert opinion process to develop a definition of early Crohn's disease (CD) that could be used in future disease-modification trials. Nineteen experts on inflammatory bowel diseases held an international expert opinion meeting to discuss and agree on a definition for early CD to be used in disease-modification trials. The process included literature searches for the relevant basic-science and clinical evidence. A published preliminary definition of early CD was used as the basis for development of a proposed definition that was discussed at the expert opinion meeting. The participants then derived a final definition, based on best current knowledge, that it is hoped will be of practical use in disease-modification trials in CD. Am J Gastroenterol 2012;107:1770-1776; doi:10.1038/ajg.2012.117
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据
分享论文
